Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 100,500 shares, an increase of 1,004.4% from the October 31st total of 9,100 shares. Based on an average daily volume of 320,400 shares, the days-to-cover ratio is presently 0.3 days.

Astellas Pharma Trading Up 0.3 %

OTCMKTS ALPMY traded up $0.03 during trading on Wednesday, hitting $10.17. 306,746 shares of the company’s stock traded hands, compared to its average volume of 185,543. The firm has a market cap of $18.40 billion, a P/E ratio of 16.90 and a beta of 0.36. The stock has a fifty day moving average of $11.38 and a two-hundred day moving average of $10.98. The company has a debt-to-equity ratio of 0.26, a current ratio of 0.90 and a quick ratio of 0.72. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. The firm had revenue of $3.11 billion during the quarter. As a group, sell-side analysts expect that Astellas Pharma will post 0.61 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.